These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

720 related articles for article (PubMed ID: 29160144)

  • 21. Pimavanserin.
    Hunter NS; Anderson KC; Cox A
    Drugs Today (Barc); 2015 Nov; 51(11):645-52. PubMed ID: 26744739
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Pimavanserin for patients with Parkinson's disease psychosis: a randomised, placebo-controlled phase 3 trial.
    Cummings J; Isaacson S; Mills R; Williams H; Chi-Burris K; Corbett A; Dhall R; Ballard C
    Lancet; 2014 Feb; 383(9916):533-40. PubMed ID: 24183563
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Treatment Possibilities for Psychosis in Parkinson's Disease with An Emphasis on the Newly Approved Drug: Pimavanserin.
    Majlath Z; Obal I; Vecsei L
    CNS Neurol Disord Drug Targets; 2017; 16(3):234-243. PubMed ID: 27719624
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [Parkinson's disease and psychoses].
    Bizzarri JV; Giupponi G; Maniscalco I; Schroffenegger P; Conca A; Kapfhammer HP
    Neuropsychiatr; 2015; 29(1):1-13. PubMed ID: 25586068
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Psychosis in Parkinson's disease.
    Thanvi BR; Lo TC; Harsh DP
    Postgrad Med J; 2005 Oct; 81(960):644-6. PubMed ID: 16210460
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Hallucinations and the spectrum of psychosis in Parkinson's disease.
    Frei K; Truong DD
    J Neurol Sci; 2017 Mar; 374():56-62. PubMed ID: 28108020
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Psychosis in Parkinson's disease: identification, prevention and treatment.
    Levin J; Hasan A; Höglinger GU
    J Neural Transm (Vienna); 2016 Jan; 123(1):45-50. PubMed ID: 25894288
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Psychosis in Parkinson's disease: diagnosis and treatment.
    Doraiswamy M; Martin W; Metz A; Deveaugh-Geiss J
    Prog Neuropsychopharmacol Biol Psychiatry; 1995 Sep; 19(5):835-46. PubMed ID: 8539422
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Guidance for switching from off-label antipsychotics to pimavanserin for Parkinson's disease psychosis: an expert consensus.
    Black KJ; Nasrallah H; Isaacson S; Stacy M; Pahwa R; Adler CH; Alva G; Cooney JW; Kremens D; Menza MA; Meyer JM; Patkar AA; Simuni T; Morrissette DA; Stahl SM
    CNS Spectr; 2018 Dec; 23(6):402-413. PubMed ID: 30588905
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Parkinson's disease psychosis 2010: a review article.
    Friedman JH
    Parkinsonism Relat Disord; 2010 Nov; 16(9):553-60. PubMed ID: 20538500
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Parkinson's disease psychosis: therapy tips and the importance of communication between neurologists and psychiatrists.
    Martinez-Ramirez D; Okun MS; Jaffee MS
    Neurodegener Dis Manag; 2016 Aug; 6(4):319-30. PubMed ID: 27408981
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Psychosis in Parkinson's Disease: A Lesson from Genetics.
    Angelopoulou E; Bougea A; Papageorgiou SG; Villa C
    Genes (Basel); 2022 Jun; 13(6):. PubMed ID: 35741861
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Neurological commentary addressing the article titled "Guidance for switching from off-label antipsychotics to pimavanserin for Parkinson's disease psychosis: an expert consensus".
    Hermanowicz N
    CNS Spectr; 2018 Dec; 23(6):352-354. PubMed ID: 30588904
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Psychosis in Parkinson's disease.
    Poewe W
    Mov Disord; 2003 Sep; 18 Suppl 6():S80-7. PubMed ID: 14502660
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pathophysiology and treatment of psychosis in Parkinson's disease: a review.
    Zahodne LB; Fernandez HH
    Drugs Aging; 2008; 25(8):665-82. PubMed ID: 18665659
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Treatment of Parkinson's disease. Psychological disorders: striking a balance in order to optimise antiparkinsonian treatment.
    Prescrire Int; 2011 Oct; 20(120):242-5. PubMed ID: 21970092
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Behavioral effects of clozapine, pimavanserin, and quetiapine in rodent models of Parkinson's disease and Parkinson's disease psychosis: evaluation of therapeutic ratios.
    Hubbard D; Hacksell U; McFarland K
    Behav Pharmacol; 2013 Oct; 24(7):628-32. PubMed ID: 23969614
    [TBL] [Abstract][Full Text] [Related]  

  • 38. What we have learned about sleep disorders and psychosis after nearly two centuries of Parkinson's disease. Summary and conclusions.
    Fernandez HH
    CNS Spectr; 2008 Mar; 13(3 Suppl 4):34-5. PubMed ID: 18323765
    [No Abstract]   [Full Text] [Related]  

  • 39. [Pimavanserin: a new treatment for the Parkinson's disease psychosis].
    Duits JH; Ongering MS; Martens HJM; Schulte PFJ
    Tijdschr Psychiatr; 2017; 59(9):528-536. PubMed ID: 28880354
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Psychosis in Parkinson's Disease: Current Treatment Options and Impact on Patients and Caregivers.
    Segal GS; Xie SJ; Paracha SU; Grossberg GT
    J Geriatr Psychiatry Neurol; 2021 Jul; 34(4):274-279. PubMed ID: 34219522
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 36.